Search Results

3.Hepatitis C Viral Kinetics as a Determinant of Stopping Pegylated Interferon and Ribavirin in Genotype 1 Infection.

Gut and Liver 2014;8(4):335-336

4.Oromucosal Cytokine Therapy: Mechanism(s) of Action.

The Korean Journal of Hepatology 2002;8(2):125-131

Oromucosal cytokine therapy allows large amounts of cytokines to be administered with improved outcome and without dose limiting toxicity. Orally administered cytokines exert their effects by a novel two pronged mechanism of action. Firstly, specific populations of immuno-competent effector cells are activated in the oral cavity and migrate to the site of virus replication. Secondly, chemokines produced in the lymphoid tissue of the oral cavity enter the peripheral circulation and redirect activated lymphocytes to eliminate virus infected cells. Oromucosal IFN therapy constitutes an alternative and improved means of therapy for diseases such as chronic viral hepatitis which are currently treated parenterally with IFN alpha. The oral route also has obvious advantages for ease of administration and improved patient compliance. Furthermore, the availability of a well tolerated form of IFN therapy will also allow Type I IFNs to be used for the treatment of diseases such as upper respiratory tract virus infections, for which parenteral IFN therapy is currently precluded due to unacceptable toxicity.
Administration, Oral ; Animals ; Antineoplastic Agents/administration & dosage ; Antiviral Agents/*administration & dosage/adverse effects/pharmacology ; Hepatitis, Viral, Human/drug therapy ; Human ; Interferon-alpha/*administration & dosage/adverse effects/pharmacology

5.Prophylaxis Against Hepatitis B Recurrence Following Liver Transplantation.

Kyung Suk SUH

The Korean Journal of Hepatology 2005;11(1):21-24

6.Preparation of acyclovir liposome and study on its stability.

Jun WU ; Jia-bi ZHU

Acta Pharmaceutica Sinica 2003;38(7):552-554

AIMTo prepare acyclovir liposome for improvement the entrapment efficiency and stability.

METHODSAcyclovir liposome was prepared by the reverse evaporating method. Surfactants such as sodium deoxycholate and oleic acid were added to optimize the conditions and technology of preparing acyclovir liposome. The entrapment efficiency and particle size of the acyclovir liposome were determined. The liposome stability was proved by centrifugal acceleration experiment.

RESULTSThe particle size of the acyclovir liposome was 219.8 nm with the polydispersity index of 0.158. The entrapment efficiency reached 65%. The liposome was stable.

CONCLUSIONThe results suggest that the conditions and technology are stable and practical to prepare the liposome with high entrapment efficient and stability.

Acyclovir ; administration & dosage ; Antiviral Agents ; administration & dosage ; Drug Carriers ; Drug Stability ; Liposomes ; chemistry ; Particle Size ; Technology, Pharmaceutical ; methods

1.Dose and Treatment Duration of Regimen.

2.The importance of personalized optimal therapy for chronic hepatitis B patients.

3.Hepatitis C Viral Kinetics as a Determinant of Stopping Pegylated Interferon and Ribavirin in Genotype 1 Infection.

4.Oromucosal Cytokine Therapy: Mechanism(s) of Action.

5.Prophylaxis Against Hepatitis B Recurrence Following Liver Transplantation.

6.Preparation of acyclovir liposome and study on its stability.

7.Therapeutic effect of ribavirin aerosol on herpangina in children.

8.Optimal strategy for chronic hepatitis B patients receiving nucleos(t)ide analogue antiviral treatment.

9.How long should patients with chronic hepatitis B virus infection be treated.

10.How to improve the efficacy of antiviral therapy on patients with hepatitis C related cirrhosis.

Display Mode

Output Records

File Type